ReviewReviews in medical virology2025
Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3.
Review in Reviews in medical virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Molecular basis for protection and cross-protection by human antibodies targeting the parainfluenza virus hemagglutinin-neuraminidase protein.Journal of virology · 2026Article
- Article
- Landscape of Prophylactic Strategies Against Human Parainfluenza Virus Type 3.Reviews in medical virology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Human parainfluenza virus-type 3 (HPIV3) is a respiratory virus responsible for mild illnesses in most of the population and severe illnesses, such as bronchiolitis and pneumonia, in young children, immunocompromised individuals and the elderly. To date, no vaccines nor antiviral drugs have been approved against HPIV3, despite its significant burden in vulnerable people. In this review, we present both past and current prophylactic strategies against HPIV3, such as live-attenuated virus, vector-based, subunit and mRNA vaccine candidates or antibody-based passive protection. For each strategy, we give an overview of the most promising candidates evaluated in preclinical studies and we report immunogenicity and protection data from clinical trials. Finally, we discuss the most important challenges regarding those vaccine strategies and their potential administration to the different vulnerable populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.